LASA vs ORCHPHARMA: Stock Comparison
ORCHID PHARMA is the larger company by market capitalisation. LASA shows faster revenue growth, while ORCHID PHARMA shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LASA leads 1; ORCHPHARMA leads 7 of 10
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LASA | ORCHPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LASA | ORCHPHARMA |
|---|---|---|
| Live Price | ₹6.52 | ₹1,003.05 |
| Day Change | -2.54% | -1.28% |
| Volume | 46,913 | 68,916 |
| 52-Week High | ₹14.08 | ₹1,133 |
| 52-Week Low | ₹5.67 | ₹480 |
| Distance from 52W High | -53.69% | -11.47% |
Valuation
| Metric | LASA | ORCHPHARMA |
|---|---|---|
| Market Cap | ₹33 Cr | ₹5,123 Cr |
| P/E Ratio | — | 478.67x |
| P/B Ratio | — | 3.27x |
| EPS | ₹-0.71 | ₹2.35 |
| Book Value | ₹9.9 | ₹308.43 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | LASA | ORCHPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | -1.5% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | — | 0% |
| Qtr Profit Growth | 14.06% | 270.21% |
Profitability & Leverage
| Metric | LASA | ORCHPHARMA |
|---|---|---|
| ROE | -68.7% | 3.3% |
| ROCE | -57.92% | 3.77% |
| Net Margin | -135.6% | 2.51% |
| Operating Margin | -136.12% | 7.2% |
| Debt to Equity | 0.2x | 0.13x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | LASA | ORCHPHARMA |
|---|---|---|
| Promoter Holding | 53.65% | 69.84% |
| FII Holding | 0% | 0.81%▼ 0.06 pp |
| DII Holding | 0% | 20.75%▲ 0.5 pp |
| Public Holding | 46.35% | 8.61%▼ 0.44 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LASA and ORCHID PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.